UNSPSC 51332505: Bromperidol

This classification denotes an antipsychotic agent with the molecular formula C21H23BrFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LYH6F7I22E, chemically known as 1-butanone, 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as bromperidol, which bears US NIH Compound Identifier 2448. Bromperidol most often comes in base and decanoate forms. European Medicines Agency schedules Bromperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05923MIG.

UNSPSC 51332505 Bromperidol, a Commodity code, nominally describes a single pharmaceutical product, but state and local solicitations tagged under this code are actually procuring a broader range of pharmaceuticals, naloxone products, drug deactivation systems, and generic multi-source medications with over-the-counter products through cooperative purchasing and direct county procurement channels. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope ranges from acute-need procurement of naloxone and drug deactivation systems for community health initiatives to larger catalog management of generic pharmaceuticals distributed through authorized wholesalers to state and local government facilities across multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—note the date discrepancy in the source) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, under a two-year contract with one-year renewal option. The Texas Health and Human Services Commission issued an RFI in early April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP on January 20, 2026 (due March 26, 2026) for multiple contracts supplying generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) to participating state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. Vendors in the MMCAP procurement must maintain $5,000,000 commercial general liability insurance and comply with cGMP and Drug Supply Chain Security Act requirements.